In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Survival after cardiac resynchronization therapy: results from 50,084 implantations

Session Rapid Fire 5: improving the response to cardiac resynchronization therapy: emerging technologies

Speaker Francisco Leyva

Congress : EHRA 2019

  • Topic : arrhythmias and device therapy
  • Sub-topic : Cardiac Resynchronization Therapy
  • Session type : Rapid Fire Abstracts
  • FP Number : 918

Authors : A Zegard (Birmingham,GB), O Okafor (Birmingham,GB), J Debono (Birmingham,GB), D Mcnulty (Birmingham,GB), A Ahmed (Birmingham,GB), H Marshall (Birmingham,GB), D Ray (London,GB), T Qiu (Birmingham,GB), F Leyva (Birmingham,GB)


A Zegard1 , O Okafor1 , J Debono2 , D Mcnulty2 , A Ahmed1 , H Marshall2 , D Ray3 , T Qiu2 , F Leyva1 , 1Aston University - Birmingham - United Kingdom , 2Queen Elizabeth Hospital Birmingham - Birmingham - United Kingdom , 3 NHS Digital and Farr Institute, London, United Kingdom - London - United Kingdom ,


Background: Randomized, controlled trials have shown that cardiac resynchronization therapy (CRT) prolongs survival in patients with heart failure (HF). No studies have explored survival after CRT in relation to individuals in the general population (relative survival, RS).

Objective: To determine observed and RS after CRT in a nationwide cohort undergoing CRT.

Methods: A national administrative database was used to quantify observed mortality for patients undergoing CRT. Relative survival (RS) was quantified using life tables.

Results: In 50,084 patients (age: 72.1±11.6 years [mean ± SD]) undergoing with (CRT-D) (n=25,273) or without (CRT-P) defibrillation (n=24,811) over 8.8 years (median follow-up 2.7 years (interquartile range [IQR]: 1.3-4.8), expected survival decreased with age. Device type, male sex, ischaemic heart disease, diabetes and chronic kidney disease predicted excess mortality. In multivariate analyses, excess mortality (analogue of RS) was lower after CRT-D than after CRT-P in all patients (adjusted hazard ratio [aHR]: 0.80; 95% confidence interval [C.I] 0.76-0.84) as well as in subgroups with (aHR:0.79;95% C.I. 0.74-0.84) or without (aHR:0.82;95% C.I. 0.74-0.91) ischaemic heart disease. A Charlson co-morbidity index (CCI) =3 portended a higher excess mortality (aHR: 3.04; 95% C.I. 2.76-3.34). RS was higher in 2015-2017 than in 2009-2011 (aHR:0.64;95%C.I. 0.59-0.69).

Conclusions Reference RS data after CRT is presented. Sex, ischaemic heart disease, diabetes, chronic kidney disease and CCI were major determinants of RS after CRT. CRT-D was associated with a higher RS than CRT-P in patients with or without ischaemic heart disease. RS after CRT improved from 2009 to 2017.

The free consultation period for this content is over.

It is now only available year-round to EHRA Ivory (& above) Members, Fellows of the ESC and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are